Loading...

Ondine Biomedical Inc.

OBI.LLSE
Healthcare
Biotechnology
£13.00
£0.00(0.00%)

Ondine Biomedical Inc. (OBI.L) Company Profile & Overview

Explore Ondine Biomedical Inc.’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.

Ondine Biomedical Inc. (OBI.L) Company Profile & Overview

Ondine Biomedical Inc., a Life sciences company, engages in the research, development, and commercialization of antimicrobial photodisinfection therapies in Canada and internationally. Its product platform is Photodisinfection, a topical light-based antimicrobial technology that eliminates harmful pathogens. The company's lead product is Steriwave, a photodisinfection based medical device that eliminates harmful nasal pathogens, which leads to healthcare-associated infections. Its product pipeline also includes development of a topical antiviral therapy for the upper respiratory tract that reduces SARS-CoV-2 titre and transmission; a solution for treatment of chronic rhinosinusitis; OND1002, a solution for disinfection of endotracheal tubes to reduce the incidence of ventilator-associated pneumonia; and OND1003, a solution for decolonization of burns and wounds. The company was incorporated in 1996 and is headquartered in Vancouver, Canada.

SectorHealthcare
IndustryBiotechnology
CEOCarolyn M. Cross MBA

Contact Information

604-669-0555
1100 Melville Street, Vancouver, BC, V6E 4A6

Company Facts

18 Employees
IPO DateDec 6, 2021
CountryCA
Actively Trading

Frequently Asked Questions

;